First in human phase I study of BSI-201, a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in subjects with advanced solid tumors

被引：43
|
作者：
Kopetz, S.
Mita, M. M.
Mok, I.
Sankhala, K. K.
Moseley, J.
Sherman, B. M.
Bradley, C. R.
Tolcher, A. W.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Canc Therapy & Res Ctr S Texas, San Antonio, TX 78229 USA
[3] BiPar Sci, Brisbane, CA USA
[4] S Texas Accelerated Res Therapeut, San Antonio, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
10.1200/jco.2008.26.15_suppl.3577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3577
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Leonard J. Appleman
    Jan H. Beumer
    Yixing Jiang
    Yan Lin
    Fei Ding
    Shannon Puhalla
    Leigh Swartz
    Taofeek K. Owonikoko
    R. Donald Harvey
    Ronald Stoller
    Daniel P. Petro
    Hussein A. Tawbi
    Athanassios Argiris
    Sandra Strychor
    Marie Pouquet
    Brian Kiesel
    Alice P. Chen
    David Gandara
    Chandra P. Belani
    Edward Chu
    Suresh S. Ramalingam
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 1289 - 1301
  • [22] Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies
    Appleman, Leonard J.
    Beumer, Jan H.
    Jiang, Yixing
    Lin, Yan
    Ding, Fei
    Puhalla, Shannon
    Swartz, Leigh
    Owonikoko, Taofeek K.
    Harvey, R. Donald
    Stoller, Ronald
    Petro, Daniel P.
    Tawbi, Hussein A.
    Argiris, Athanassios
    Strychor, Sandra
    Pouquet, Marie
    Kiesel, Brian
    Chen, Alice P.
    Gandara, David
    Belani, Chandra P.
    Chu, Edward
    Ramalingam, Suresh S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (06) : 1289 - 1301
  • [23] Testing of a poly(ADP-ribose) polymerase ( PARP) inhibitor on human BRCA2 heterozygous cell lines
    Halldorsdottir, A. M.
    Vidarsdottir, L.
    Stefansson, O. A.
    Bjarnason, H.
    Bodvarsdottir, S. K.
    Eyfjord, J. E.
    EJC SUPPLEMENTS, 2010, 8 (05): : 57 - 57
  • [24] Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial
    O'Shaughnessy, J.
    Osborne, C.
    Pippen, J.
    Yoffe, M.
    Patt, D.
    Monaghan, G.
    Rocha, C.
    Ossovskaya, V.
    Sherman, B.
    Bradley, C.
    EJC SUPPLEMENTS, 2009, 7 (03): : 7 - 7
  • [25] Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial
    O'Shaughnessy, J.
    Osborne, C.
    Pippen, J.
    Yoffe, M.
    Patt, D.
    Monaghan, G.
    Rocha, C.
    Ossovskaya, V.
    Sherman, B.
    Bradley, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [26] First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.
    Samnotra, Vivek
    Shtessel, Veronica Moroz Luda
    Kuchimanchi, Mita
    Hanafin, Patrick
    Pannirselvam, Malar
    Bhaskar, Aishwarya
    Liu, Andrew
    Yuzugullu, Haluk
    Barve, Minal A.
    Sommerhalder, David
    Yap, Timothy A.
    Sanicola-Nadel, Michele
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Preliminary results of a phase I trial of ABT-888, a poly(ADP-ribose) polymerase (PARP) inhibitor, in combination with cyclophosphamide.
    Tan, A. R.
    Gibbon, D.
    Stein, M. N.
    Moss, R. A.
    Karantza, V.
    Lin, H.
    Gounder, M.
    Chen, A. P.
    Egorin, M. J.
    DiPaola, R. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (KU), a small molecule inhibitor of poly ADP-RIBOSE polymerase (PARP) in cancer patients (P), including BRCA 1/2 mutation carriers
    de Bono, J.
    Boss, D.
    Fong, P.
    Roelvink, M.
    Yap, T.
    Tutt, A.
    Mortimer, P.
    O'Connor, M.
    Schellens, J. H.
    Kaye, S.
    ANNALS OF ONCOLOGY, 2007, 18 : 26 - 27
  • [29] DESIGN AND SYNTHESIS OF NOVEL POLY ADP-RIBOSE POLYMERASE 1 (PARP1) INHIBITORS FOR THE TREATMENT OF SOLID TUMORS
    Priyancy, J.
    Bhumika, D. P.
    CONFERENCE ON DRUG DESIGN AND DISCOVERY TECHNOLOGIES, 2020, 355 : 31 - 35
  • [30] First-in-class first-in-human phase 1 trial and translational study of the mono(ADP-ribose) polymerase-7 (PARP7) inhibitor RBN-2397 in patients with selected advanced solid tumors
    Yap, Timothy A.
    Cervantes, Andres
    Falchook, Gerald S.
    Patel, Manish R.
    Juric, Dejan
    Waqar, Saiama N.
    Schenk, Erin L.
    Shapiro, Geoffrey
    Boni, Valentina
    Perez, Cesar A.
    Burtness, Barbara
    Najjar, Yana G.
    Racca, Fabricio
    Rojas, Katerin
    Kuplast-Barr, Kristy
    McEachern, Kristen
    Samant, Manoj
    Bozon, Viviana
    Parasuraman, Sudha
    Johnson, Melissa
    CANCER RESEARCH, 2023, 83 (08)
12345